|
CDER Patient-Focused Drug Development
Public Meeting on Patient-Focused Drug Development for Long COVID
On April 25th, 2023, FDA is hosting a virtual public meeting on Patient-Focused Drug Development for Long COVID. This meeting will provide FDA the opportunity to obtain initial patient and patient representative input on the aspects of Long COVID, including how Long COVID affects their daily life, symptoms that matter most to patients, their current approaches to treating Long COVID, and what they consider when determining whether or not to participate in a clinical trial. This virtual public meeting will be conducted with live translation in both English and Spanish.
The event information webpage, Public Meeting on Patient-Focused Drug Development for Long COVID - 04/25/2023 | FDA. (en Español) includes free registration and will be updated as meeting materials become available.
FDA encourages participants to submit written comments to the public docket, FDA-2023-N-0363-0001, by June 26, 2023.
Social media posts on this subject:
Additional information about the meeting can be found on the meeting webpage. The meeting webpage will be updated as meeting materials are developed.
|
|
|
To contact FDA's CDER Patient-Focused Drug Development Program Staff, please email patientfocused@fda.hhs.gov.
If this message was forwarded to you and you would like to subscribe to this free email subscription service, please visit our CDER PFDD Homepage and click the button "Subscribe to Email Updates" at the top of the page.
|
|
|
|
